奥妥珠单抗成功治疗利妥昔单抗难治性PLA2R相关膜性肾病3例报告
本文报告3例PLA2R相关膜性肾病患者,利妥昔单抗未能诱导免疫学或临床缓解,改用奥妥珠单抗后全部获得完全免疫学缓解,其中2例获得部分临床缓解。提示奥妥珠单抗可能是利妥昔单抗难治性PLA2R相关膜性肾病的有效治疗选择。
要点
- 利妥昔单抗治疗PLA2R相关膜性肾病,高达40%患者可能无应答。
- 3例利妥昔单抗难治性患者经奥妥珠单抗治疗后均获完全免疫学缓解。
- 奥妥珠单抗治疗后2例获得部分临床缓解,安全性未报告。
核心结论
- 奥妥珠单抗对利妥昔单抗难治性PLA2R相关膜性肾病可能有效,3例均获完全免疫学缓解。
研究设计与样本
- 病例报告,纳入3例利妥昔单抗治疗失败的PLA2R相关膜性肾病患者。
主要发现
- 奥妥珠单抗使3例均获得完全免疫学缓解,其中2例随后获得部分临床缓解。
关键数值与推荐
- 利妥昔单抗治疗失败定义为未诱导免疫学或临床缓解。
- 完全免疫学缓解和部分临床缓解的定义原文未报告。
临床怎么用
- 对利妥昔单抗无应答的PLA2R相关膜性肾病患者,可考虑试用奥妥珠单抗。
局限性
- 仅为3例病例报告,证据等级低,结论需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. Rituximab, a type I anti-CD20 antibody, has been shown to be an effective therapy in treatment of patients with MN associated with M-type phospholipase A2 receptor (PLA2R) antibodies. Despite its effectiveness, up to 40% of patients may fail to respond to rituximab, which may be related to higher PLA2R antibody titers. Obinutuzumab, a type II anti-CD20 depleter, has been shown to produce a more profound CD20 depletion and be more efficacious in treating certain hematologic malignancies compared with rituximab. We report 3 patients with PLA2R-associated MN for whom rituximab failed to induce immunologic or clinical remisison, but who were successfully treated with obinutuzumab. Obinutuzumab resulted in complete immunologic remission in all 3 cases and was followed by partial remission in 2 of the cases. Obinutuzumab appears to be a promising treatment strategy for PLA2R-associated MN that fails to respond to rituximab.
引用
- Klomjit N, Fervenza FC, Zand L, et al. Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases. Am J Kidney Dis. 2020. PMID: 32311405. doi:10.1053/j.ajkd.2020.02.444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。